Xconomy -- Acetylon Pharmaceuticals, a developer of drugs that inhibit HDAC enzymes to treat cancer and autoimmune diseases, has raised $12.4 million of a proposed $30 million second round of equity financing, according to an SEC filing.
Xconomy -- Acetylon Pharmaceuticals, a developer of drugs that inhibit HDAC enzymes to treat cancer and autoimmune diseases, has raised $12.4 million of a proposed $30 million second round of equity financing, according to an SEC filing.
